{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014793","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.212028+00:00","generated_at":"2026-05-29T19:48:11.848147+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences regains Nasdaq minimum bid price compliance","bullets":["Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).","Avoids imminent delisting from Nasdaq; common stock (NDRA) continues trading.","Acting CEO Alex Tokman says company will now focus on new transformational strategies."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014793","json":"https://secwatch.observer/filing/0001654954-24-014793.json","markdown":"https://secwatch.observer/filing/0001654954-24-014793.md","text":"https://secwatch.observer/filing/0001654954-24-014793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424014793/0001654954-24-014793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424014793/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:48:11.848147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}